Aptevo Therapeutics Inc. - 8-K Filing
Aptevo reports 93% clinical benefit rate with mipletamig triplet in TP53-mutated frontline AML patients (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $APVO
More Regulatory news
- Boost Run Inc. - 8-K Filing
- INTERFACE INC - 8-K Filing
- Neonode Inc. - 10-Q Filing
- Virtuix Holdings Inc. - 8-K Filing
- Neonode Inc. - 8-K Filing
- Beyond Air, Inc. - 10-Q Filing
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing